View NSN Online: https://aerobasegroup.de/nsn/6505-01-346-4821

CIBA-GEIGY CORP GEIGY PHARMACEUTICALS DIV -- LOTENSIN TABLET, CODE#:NDC 0083-0079-30. -- 6505-01-346-4821 Product ID:LOTENSIN TABLET, CODE#:NDC 0083-0079-30. MSDS Date:12/10/1992 FSC:6505 NIIN:01-346-4821 MSDS Number: BTSKW === Responsible Party === Company Name: CIBA-GEIGY CORP GEIGY PHARMACEUTICALS DIV Address:556 MORRIS AVE City:SUMMIT State:NJ ZIP:07901-1303 С ountry:US Info Phone Num:201-277-5452 Emergency Phone Num:201-277-5452/908-277-6397 CAGE:0267X === Contractor Identification === Company Name: CIBA-GEIGY CORP Address:4917 DAWN AVE Box:18300 **City:EAST LANSING** State:MI ZIP:48823-5605 Country:US Phone:517-351-5900 CAGE:0267X Company Name: CIBA-GEIGY CORP, GEIGY PHARMACEUTICALS DIV Address:556 MORRIS AVE Box:City:SUMMIT State:NJ ZIP:07901-1303 Country:US Phone:201-277-5452 CAGE:97423

======= Composition/Information on Ingredients ==========

=

Ingred Name:LACTOSE, NF CAS:63-42-3 RTECS #:OD9625000 Fraction by Wt: 55.3-76% Other REC Limits:NONE RECOMMENDED

Ingred Name:BENAZEPRIL HYDROCHLORIDE CAS:86541-74-4 Fraction by Wt: 2.7-23% Other REC Limits:NONE RECOMMENDED

Ingred Name:MICROCRYSTALLINE CELLULOSE, NF CAS:9004-34-6 RTECS #:FJ5691460 Fraction by Wt: 9.7-14% Other REC Limits:NONE RECOMMENDED OSHA PEL:15 MG/M3 TDUST ACGIH TLV:10 MG/M3; 9394

Ingred Name:PREGELATINIZED STARCH, NF CAS:9005-25-8 RTECS #:GM5090000 Fraction by Wt: 4.3 -4.5% Other REC Limits:NONE RECOMMENDED OSHA PEL:15 MG/M3 TDUST ACGIH TLV:10 MG/M3; 9394

LD50 LC50 Mixture:LD50 (ORAL,RAT) > 5000MG/KG. Routes of Entry: Inhalation:NO Skin:NO Ingestion:NO Reports of Carcinogenicity:NTP:NO IARC:NO OSHA:NO Health Hazards Acute and Chronic:LOTENSIN IS A FINISHED PHARMACEUTICAL PRODUCT.POTENTIAL FOR EXPOSURE REDUCED IN THIS FORM.SIDE AFFECTS OF THERAPEUTIC USE AS TREATMENT FOR HYP ERTENSION:HEADACHE,COUGH,HYPOTENSION,DIZZ,FATIGUE,NAU,ANGI

OEDEMA(FACE,TONGUE,EXTREMITIES),DERM.ACE INHIBITOR:MAY CAUSE FETAL INJURY & DEATH WHEN USED IN 2ND & 3RD TRIMESTERS PREG Effects of Overexposure:SIDE AFFECTS OF THERAPEUTIC USE AS TREATMENT

FOR HYPERTENSION:HEADACHE, COUGH, HYPOTENSION, DIZZ, FATIGUE, NAUS, ANGIOEDEMA (FACE, TONGUE, EXTREMITIES), DERM. ACE INHIBITOR:MAY CAUSE FETAL INJURY & DE ATH WHEN USED IN 2ND & 3RD TRIMESTERS OF PREGNANCY. Medical Cond Aggrav

Medical Cond Aggrav

ated by Exposure:HYPERSENSITIVITY TO ACE INHIBITORS; PRE-EXISTING IMPAIRED RENAL FUNCTION; AVOID DURING PREGNANCY.

First Aid:INHAL:REMOVE TO FRESH AIR. EYE:FLUSH WITH RUNNING WATER FOR 15 MINS. SKIN: WASH CONTAMINATED AREA WITH SOAP & WATER. Extinguishing Media: USE MEDIA SUITABLE FOR FIRE IN SURROUNDING AREA. Fire Fighting Procedures:WEAR FULL PROTE CTIVE CLOTHING AND SELF-CONTAINED BREATHING APPARATUS. Unusual Fire/Explosion Hazard:NOT AVAILABLE. Spill Release Procedures: USING APPROPRIATE PROTECTIVE EQUIPMENT SWEEP UP AND CONTAINERIZE SPILLED MATERIAL. RESIDUES MAY BE FLUSHED TO THE SANITARY SEWER WITH WATER. Neutralizing Agent:NONE SPECIFIED BY MANUFACTURER. Handling and Storage Precaution s:DO NOT STORE ABOVE 86F (30C). PROTECT FROM MOISTURE. DISPENSE IN TIGHT CONTAINER. Other Precautions: REFER TO PACKAGE AND PATIENT INFORMATIN INSERTS. REFER TO PHYSICIAN'S DESK REFERENCE. Respiratory Protection:NOT REQUIRED UNDER NORMAL CONDITIONS OF THERAPEUTIC USE. Ventilation:NOT REQUIRED UNDER NORMAL CONDITIONS OF THERAPEUTIC USE. Protective Gloves:N/R UNDER NOR CONDITIONS OF THERAP USE. Eye Protection:N/R UNDE R NOR CONDITIONS OF THERAP USE. Other Protective Equipment:NONE. Work Hygienic Practices: WASH HANDS AFTER HANDLING PRODUCT. Supplemental Safety and Health SLIGHTLY TOXIC. MAY BE FETOTOXIC. PER TIR:20MG BENAZEPRIL HYDROCHLORIDE. HCC:N1 Solubility in Water:SOLUBLE Appearance and Odor:YELLOW, TAN OR ROSE TABLET.

Stability Indicator/Materials to Avoid:YES

ONE SPECIFIED BY MANUFACTURER. Stability Condition to Avoid:DO NOT STORE ABOVE 86F. PROTECT FROM MOISTURE. DISPENSE IN A TIGHT CONTAINER. Hazardous Decomposition Products:NONE SPECIFIED BY MANUFACTURER.

Waste Disposal Methods: ALL WASTES WILL BE SENT TO AN APPROPRIATE, APPROVED DISPOSAL FACILITY FOLLOWING STANDARD OPERATING PROCEDURES.

Disclaimer (provided with this information by the compiling agencies): This inform

ation is formulated for use by elements of the Department of Defense. The United States of America in no manner whatsoever, expressly or implied, warrants this information to be accurate and disclaims all liability for its use. Any person utilizing this document should seek competent professional advice to verify and assume responsibility for the suitability of this information to their particular situation.